MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$152M

Net Income

-$148M

EPS (Diluted)

$-7.38

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$149M

Free Cash Flow

-$150M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$232M

Stockholders' Equity

$851M

Cash & Equivalents

$623M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$152M	-$78M	-94.1%
Net Income	-$148M	-$77M	-91.9%

MDGL Q1 2024 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena